Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns
Executive Summary
Questions about US FDA's handling of orphan indications may arise again during upcoming Oncologic Drugs Advisory Committee meeting on ABP215, a proposed Avastin biosimilar.